Coldstream Capital Management Inc. Raises Position in Gilead Sciences, Inc. $GILD

Coldstream Capital Management Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,726 shares of the biopharmaceutical company’s stock after buying an additional 8,807 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Gilead Sciences were worth $3,966,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $26,000. Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences during the second quarter worth about $30,000. MTM Investment Management LLC increased its position in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC purchased a new stake in Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Millstone Evans Group LLC lifted its position in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 2.2%

Shares of GILD opened at $141.29 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a market cap of $175.40 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 1.89 and a beta of 0.37. The firm has a 50 day moving average price of $141.96 and a 200-day moving average price of $127.51. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is 48.45%.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 309,280 shares of company stock worth $44,068,850 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly beat, raised guidance and dividend increase provide fundamental support — Gilead reported $1.86 EPS (vs. $1.83 est.), $7.93B revenue (vs. $7.68B est.), set FY‑2026 EPS guidance of $8.45–$8.85 and raised the quarterly dividend to $0.82. Those elements support longer‑term upside.
• Positive Sentiment: M&A/sector takeover chatter (Arcellx coverage) is reviving speculation that Gilead may pursue deals to bolster its cell‑therapy/oncology pipeline — a catalyst investors treat as strategic upside. Fool: Arcellx / takeover-related coverage
• Neutral Sentiment: Unusual options activity flagged by scanners — heightened option flow can signal hedging or speculative bets; it’s ambiguous until directional put/call skew and volume patterns solidify. Barchart: options activity
• Neutral Sentiment: Analysts show mixed/contrasting views — some firms have raised targets and reiterated buys while others are more cautious, so research flow is creating both support and headlines that can move sentiment. Globe and Mail: analysts conflicting
• Neutral Sentiment: New coverage of potential CAR‑T competitors (Estrella/ESLA) is worth watching but is not an immediate direct threat to Gilead’s larger, diversified franchise — more a sector development. Yahoo: ESLA coverage
• Negative Sentiment: Insider selling by senior executives — Johanna Mercier and CFO Andrew D. Dickinson each sold 3,000 shares (average ~$144.23) recently; multiple insider sales can sour near‑term sentiment even if part of planned diversification. InsiderTrades: insider sales
• Negative Sentiment: Recent headlines and retail coverage are bearish — pieces arguing to “avoid GILD” are amplifying outflows/weakness among some investors and may pressure the intraday move. Yahoo: 3 Reasons to Avoid GILD
• Negative Sentiment: Market‑coverage note reporting Gilead fell more than the broader market today — a short‑term confirmation of downward price pressure that may trigger additional technical selling. Zacks: GILD falls more than market

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Wells Fargo & Company raised their price target on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.